Yessir, these early biotechs are cash cows for hedge operators who run them up and down until the binary event. The kicker is what they do for the end game. I'm betting Adage still views this as a good long play which has now been accelerated by the somewhat recent plan to go for EU commercialization. It is a fairly recent development which changed the timeline.
News 
Market Data 
Discover 
